# Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia

> **NCT00337662** · PHASE4 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 628 (actual)

## Conditions studied

- Schizophrenia
- Schizoaffective Disorder
- Schizophreniform Disorder

## Interventions

- **DRUG:** olanzapine
- **DRUG:** risperidone
- **DRUG:** risperidone

## Key facts

- **NCT ID:** NCT00337662
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 628 (ACTUAL)
- **Last updated:** 2010-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00337662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00337662, "Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00337662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*